HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Donna Karan beauty business

This article was originally published in The Rose Sheet

Executive Summary

Revenues for FY 1997 (ended Dec. 28) fell to $18.7 mil., compared to $43.7 mil. in the prior year, partially due to the wind- down of operations following the licensing agreement with Estee Lauder, Donna Karan announced March 23. The company took a $23.4 mil. charge related to the licensing deal for the year. In the fourth quarter, beauty business revenues were "negligible," compared to $20.1 mil. in the corresponding period of FY 1996. Consolidated revenues for the fashion house increased 4.2% to $638.7 mil. on a pro forma basis, assuming that Donna Karan's initial public offering (July 3, 1996) occurred on the first day of FY 1996. The company reported an $81.4 mil. loss compared to net income of $12.9 mil. the prior year...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel